# Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2025-financial-results
Ticker: SNGX
Company: SOLIGENIX
Source: SOLIGENIX
Published: 2026-03-31 11:30 EST
Original Source URL: https://ir.soligenix.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-08 11:30 EST — [Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine](https://biopharmsignal.com/news/SNGX/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-a724aab6) — Source: SOLIGENIX
- 2026-05-26 11:30 EST — [Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo](https://biopharmsignal.com/news/SNGX/suitability-of-vaccine-platform-for-bundibugyo-virus-cause-of-the-ebola-outbreak-in-congo) — Source: SOLIGENIX
- 2026-05-08 11:30 EST — [Soligenix Announces Recent Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results) — Source: SOLIGENIX
- 2026-04-28 11:30 EST — [Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma](https://biopharmsignal.com/news/SNGX/soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybrytetm-in-treatment-of-cutaneous-t-cell-lymphoma) — Source: SOLIGENIX
- 2026-04-02 11:30 EST — [Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy](https://biopharmsignal.com/news/SNGX/positive-clinical-results-from-hybrytetm-comparative-study-evaluating-hybrytetm-against-valchlorr-in-the-treatment-of-cutaneous-t-cell-lymphoma-published-in-oncology-and-therapy) — Source: SOLIGENIX
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)